View Financial HealthAminologicsLtd 配当と自社株買い配当金 基準チェック /06AminologicsLtd配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesNew Risk • Apr 03New major risk - Revenue and earnings growthEarnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩122.7b market cap, or US$81.3m).Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩1,555, the stock trades at a trailing P/E ratio of 70x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total loss to shareholders of 18% over the past three years.お知らせ • Mar 13Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: dasan hall, 114, taebong-ro, seocho-gu, seoul South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩1,299, the stock trades at a trailing P/E ratio of 58.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 31% over the past three years.Valuation Update With 7 Day Price Move • Jan 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩1,532, the stock trades at a trailing P/E ratio of 68.9x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 24% over the past three years.分析記事 • Jan 21AminologicsLtd (KOSDAQ:074430) Shareholders Will Want The ROCE Trajectory To ContinueThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...分析記事 • Dec 30AminologicsLtd (KOSDAQ:074430) Has A Rock Solid Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • Dec 30Subdued Growth No Barrier To Aminologics Co.,Ltd. (KOSDAQ:074430) With Shares Advancing 27%Aminologics Co.,Ltd. ( KOSDAQ:074430 ) shares have had a really impressive month, gaining 27% after a shaky period...New Risk • Dec 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩104.9b market cap, or US$72.7m).Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩1,194, the stock trades at a trailing P/E ratio of 53.7x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 33% over the past three years.分析記事 • Nov 21AminologicsLtd's (KOSDAQ:074430) Earnings Seem To Be PromisingThe market seemed underwhelmed by last week's earnings announcement from Aminologics Co.,Ltd. ( KOSDAQ:074430 ) despite...Reported Earnings • Nov 20Third quarter 2025 earnings released: EPS: ₩15.00 (vs ₩17.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩15.00 (up from ₩17.00 loss in 3Q 2024). Revenue: ₩6.01b (up 151% from 3Q 2024). Net income: ₩1.36b (up ₩2.89b from 3Q 2024). Profit margin: 23% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.分析記事 • Nov 12Risks To Shareholder Returns Are Elevated At These Prices For Aminologics Co.,Ltd. (KOSDAQ:074430)When close to half the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S") below 0.7x...New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩90.7b market cap, or US$65.4m).New Risk • Apr 01New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩78.1b market cap, or US$53.2m).お知らせ • Mar 01Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2025Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South Korea分析記事 • Nov 15There May Be Underlying Issues With The Quality Of AminologicsLtd's (KOSDAQ:074430) EarningsDespite announcing strong earnings, Aminologics Co.,Ltd.'s ( KOSDAQ:074430 ) stock was sluggish. We think that the...Reported Earnings • Nov 12Third quarter 2024 earnings released: ₩17.00 loss per share (vs ₩6.00 loss in 3Q 2023)Third quarter 2024 results: ₩17.00 loss per share (further deteriorated from ₩6.00 loss in 3Q 2023). Revenue: ₩2.39b (down 43% from 3Q 2023). Net loss: ₩1.53b (loss widened 177% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩102.1b market cap, or US$77.6m).分析記事 • Aug 13AminologicsLtd (KOSDAQ:074430) May Have Issues Allocating Its CapitalTo avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩1,157, the stock trades at a trailing P/E ratio of 39.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 61% over the past three years.分析記事 • Mar 27AminologicsLtd's (KOSDAQ:074430) Shareholders May Want To Dig Deeper Than Statutory ProfitFollowing the solid earnings report from Aminologics Co.,Ltd. ( KOSDAQ:074430 ), the market responded by bidding up the...Reported Earnings • Mar 26Full year 2023 earnings released: EPS: ₩28.00 (vs ₩83.00 loss in FY 2022)Full year 2023 results: EPS: ₩28.00 (up from ₩83.00 loss in FY 2022). Revenue: ₩20.9b (down 24% from FY 2022). Net income: ₩2.44b (up ₩9.72b from FY 2022). Profit margin: 12% (up from net loss in FY 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.分析記事 • Mar 01Some Investors May Be Worried About AminologicsLtd's (KOSDAQ:074430) Returns On CapitalWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...New Risk • Jul 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩123.4b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩123.4b market cap, or US$96.4m).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩2,465, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 14% over the past three years.Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩2,845, the stock trades at a trailing P/E ratio of 32.4x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 35% over the past three years.Valuation Update With 7 Day Price Move • May 18Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩2,645, the stock trades at a trailing P/E ratio of 43.3x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 31% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩2,310, the stock trades at a trailing P/E ratio of 37.9x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 5.0% over the past three years.Reported Earnings • Nov 13Third quarter 2021 earnings released: EPS ₩11.00 (vs ₩8.00 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₩4.41b (down 15% from 3Q 2020). Net income: ₩961.5m (up 35% from 3Q 2020). Profit margin: 22% (up from 14% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩2,345, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 19x in the Chemicals industry in South Korea. Total returns to shareholders of 8.1% over the past three years.Reported Earnings • May 19First quarter 2021 earnings released: EPS ₩10.00 (vs ₩5.00 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩4.41b (up 8.5% from 1Q 2020). Net income: ₩869.4m (up ₩1.30b from 1Q 2020). Profit margin: 20% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.分析記事 • May 05Returns At AminologicsLtd (KOSDAQ:074430) Are On The Way UpFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...分析記事 • Mar 19Should Weakness in Aminologics Co.,Ltd.'s (KOSDAQ:074430) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?With its stock down 7.9% over the past three months, it is easy to disregard AminologicsLtd (KOSDAQ:074430). But if you...Reported Earnings • Mar 19Full year 2020 earnings released: EPS ₩24.00 (vs ₩14.00 loss in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₩17.7b (down 7.0% from FY 2019). Net income: ₩2.14b (up ₩3.34b from FY 2019). Profit margin: 12% (up from net loss in FY 2019). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Mar 09New 90-day low: ₩2,400The company is down 19% from its price of ₩2,970 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.分析記事 • Feb 04If You Had Bought AminologicsLtd (KOSDAQ:074430) Stock Five Years Ago, You Could Pocket A 137% Gain TodayWhen you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...Is New 90 Day High Low • Jan 06New 90-day high: ₩3,405The company is up 49% from its price of ₩2,285 on 08 October 2020. The South Korean market is up 24% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 25% over the same period.Is New 90 Day High Low • Dec 04New 90-day high: ₩2,740The company is up 13% from its price of ₩2,415 on 04 September 2020. The South Korean market is also up 13% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Chemicals industry, which is up 12% over the same period.Is New 90 Day High Low • Oct 18New 90-day low: ₩2,030The company is down 2.0% from its price of ₩2,080 on 20 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 25% over the same period.決済の安定と成長配当データの取得安定した配当: A074430の 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: A074430の配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場AminologicsLtd 配当利回り対市場A074430 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (A074430)n/a市場下位25% (KR)1.0%市場トップ25% (KR)3.8%業界平均 (Chemicals)1.3%アナリスト予想 (A074430) (最長3年)n/a注目すべき配当: A074430は最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: A074430は最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: A074430の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: A074430が配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YKR 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 18:00終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aminologics Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Apr 03New major risk - Revenue and earnings growthEarnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩122.7b market cap, or US$81.3m).
Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩1,555, the stock trades at a trailing P/E ratio of 70x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total loss to shareholders of 18% over the past three years.
お知らせ • Mar 13Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: dasan hall, 114, taebong-ro, seocho-gu, seoul South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩1,299, the stock trades at a trailing P/E ratio of 58.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 31% over the past three years.
Valuation Update With 7 Day Price Move • Jan 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩1,532, the stock trades at a trailing P/E ratio of 68.9x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 24% over the past three years.
分析記事 • Jan 21AminologicsLtd (KOSDAQ:074430) Shareholders Will Want The ROCE Trajectory To ContinueThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
分析記事 • Dec 30AminologicsLtd (KOSDAQ:074430) Has A Rock Solid Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • Dec 30Subdued Growth No Barrier To Aminologics Co.,Ltd. (KOSDAQ:074430) With Shares Advancing 27%Aminologics Co.,Ltd. ( KOSDAQ:074430 ) shares have had a really impressive month, gaining 27% after a shaky period...
New Risk • Dec 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩104.9b market cap, or US$72.7m).
Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩1,194, the stock trades at a trailing P/E ratio of 53.7x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 33% over the past three years.
分析記事 • Nov 21AminologicsLtd's (KOSDAQ:074430) Earnings Seem To Be PromisingThe market seemed underwhelmed by last week's earnings announcement from Aminologics Co.,Ltd. ( KOSDAQ:074430 ) despite...
Reported Earnings • Nov 20Third quarter 2025 earnings released: EPS: ₩15.00 (vs ₩17.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩15.00 (up from ₩17.00 loss in 3Q 2024). Revenue: ₩6.01b (up 151% from 3Q 2024). Net income: ₩1.36b (up ₩2.89b from 3Q 2024). Profit margin: 23% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
分析記事 • Nov 12Risks To Shareholder Returns Are Elevated At These Prices For Aminologics Co.,Ltd. (KOSDAQ:074430)When close to half the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S") below 0.7x...
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩90.7b market cap, or US$65.4m).
New Risk • Apr 01New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩78.1b market cap, or US$53.2m).
お知らせ • Mar 01Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2025Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South Korea
分析記事 • Nov 15There May Be Underlying Issues With The Quality Of AminologicsLtd's (KOSDAQ:074430) EarningsDespite announcing strong earnings, Aminologics Co.,Ltd.'s ( KOSDAQ:074430 ) stock was sluggish. We think that the...
Reported Earnings • Nov 12Third quarter 2024 earnings released: ₩17.00 loss per share (vs ₩6.00 loss in 3Q 2023)Third quarter 2024 results: ₩17.00 loss per share (further deteriorated from ₩6.00 loss in 3Q 2023). Revenue: ₩2.39b (down 43% from 3Q 2023). Net loss: ₩1.53b (loss widened 177% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩102.1b market cap, or US$77.6m).
分析記事 • Aug 13AminologicsLtd (KOSDAQ:074430) May Have Issues Allocating Its CapitalTo avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩1,157, the stock trades at a trailing P/E ratio of 39.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 61% over the past three years.
分析記事 • Mar 27AminologicsLtd's (KOSDAQ:074430) Shareholders May Want To Dig Deeper Than Statutory ProfitFollowing the solid earnings report from Aminologics Co.,Ltd. ( KOSDAQ:074430 ), the market responded by bidding up the...
Reported Earnings • Mar 26Full year 2023 earnings released: EPS: ₩28.00 (vs ₩83.00 loss in FY 2022)Full year 2023 results: EPS: ₩28.00 (up from ₩83.00 loss in FY 2022). Revenue: ₩20.9b (down 24% from FY 2022). Net income: ₩2.44b (up ₩9.72b from FY 2022). Profit margin: 12% (up from net loss in FY 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.
分析記事 • Mar 01Some Investors May Be Worried About AminologicsLtd's (KOSDAQ:074430) Returns On CapitalWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
New Risk • Jul 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩123.4b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩123.4b market cap, or US$96.4m).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩2,465, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 14% over the past three years.
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩2,845, the stock trades at a trailing P/E ratio of 32.4x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 35% over the past three years.
Valuation Update With 7 Day Price Move • May 18Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩2,645, the stock trades at a trailing P/E ratio of 43.3x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 31% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩2,310, the stock trades at a trailing P/E ratio of 37.9x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 5.0% over the past three years.
Reported Earnings • Nov 13Third quarter 2021 earnings released: EPS ₩11.00 (vs ₩8.00 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₩4.41b (down 15% from 3Q 2020). Net income: ₩961.5m (up 35% from 3Q 2020). Profit margin: 22% (up from 14% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩2,345, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 19x in the Chemicals industry in South Korea. Total returns to shareholders of 8.1% over the past three years.
Reported Earnings • May 19First quarter 2021 earnings released: EPS ₩10.00 (vs ₩5.00 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩4.41b (up 8.5% from 1Q 2020). Net income: ₩869.4m (up ₩1.30b from 1Q 2020). Profit margin: 20% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.
分析記事 • May 05Returns At AminologicsLtd (KOSDAQ:074430) Are On The Way UpFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
分析記事 • Mar 19Should Weakness in Aminologics Co.,Ltd.'s (KOSDAQ:074430) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?With its stock down 7.9% over the past three months, it is easy to disregard AminologicsLtd (KOSDAQ:074430). But if you...
Reported Earnings • Mar 19Full year 2020 earnings released: EPS ₩24.00 (vs ₩14.00 loss in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₩17.7b (down 7.0% from FY 2019). Net income: ₩2.14b (up ₩3.34b from FY 2019). Profit margin: 12% (up from net loss in FY 2019). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Mar 09New 90-day low: ₩2,400The company is down 19% from its price of ₩2,970 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.
分析記事 • Feb 04If You Had Bought AminologicsLtd (KOSDAQ:074430) Stock Five Years Ago, You Could Pocket A 137% Gain TodayWhen you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
Is New 90 Day High Low • Jan 06New 90-day high: ₩3,405The company is up 49% from its price of ₩2,285 on 08 October 2020. The South Korean market is up 24% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 25% over the same period.
Is New 90 Day High Low • Dec 04New 90-day high: ₩2,740The company is up 13% from its price of ₩2,415 on 04 September 2020. The South Korean market is also up 13% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Chemicals industry, which is up 12% over the same period.
Is New 90 Day High Low • Oct 18New 90-day low: ₩2,030The company is down 2.0% from its price of ₩2,080 on 20 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 25% over the same period.